a year ago

Baseimmune Raises £9 Million to Develop ‘Mutation-Proof’ Vaccines

  • Baseimmune, a UK-based vaccine discovery biotech company, has raised £9 million in a Series A funding round led by IQ Capital with participation from existing investor Hoxton Ventures

  • The company's technology utilizes an algorithm to analyze genomic data and create artificial antigens, allowing for the development of future-proof vaccines that can protect against potential mutations

  • The funding will be used to develop more potential vaccine candidates, as Baseimmune aims to capitalize on the "patent cliff" facing big pharmaceutical companies and the increasing adoption of new technologies in the pharmaceutical industry.

      • ProblemHealthcare

      "Existing vaccines are often ineffective against new variants of diseases. This means we need to constantly develop new vaccines, which is expensive and time-consuming."

      Solution

      "Baseimmune uses an algorithm to create vaccines that are effective against both known and future variants of diseases. This means that their vaccines are more likely to be effective in the long term."

      Covered on